Oric Pharmaceuticals Inc

NASDAQ:ORICUnited States

info@oricpharma.com
ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS (in thousands, except share and per share amounts) September 30, 2024 December 31, 2023 -------------------- ------------------- (unaudited) Assets Current assets: Cash, cash equivalents and short-term investments $ 272,369 $ 208,187 Prepaid expenses and other current assets 7,059 4,410 --- --------------- --- -------------- Total current assets 279,428 212,597 Long-term investments 9,998 26,852 Property and equipment, net 3,091 2,862 Other assets 9,553 9,696 --- --------------- --- -------------- Total assets $ 302,070 $ 252,007 === =============== === ============== Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 4,249 $ 944 Accrued liabilities 16,999 19,514 --- --------------- --- -------------- Total current liabilities 21,248 20,458 Other long-term liabilities 6,828 7,461 --- --------------- --- -------------- Total liabilities 28,076 27,919 Total stockholders' equity 273,994 224,088 --- --------------- --- -------------- Total liabilities and stockholders' equity $ 302,070 $ 252,007 === =============== === ============== ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands, except share and per share amounts) Three Months Ended Nine Months Ended September 30, September 30, ------------------------- ------------------------- 2024 2023 2024 2023 ----------- ----------- ----------- ----------- Operating expenses: Research and development $ 31,202 $ 22,388 $ 82,102 $ 60,691 General and administrative 7,116 6,294 21,223 18,661 Total operating expenses 38,318 28,682 103,325 79,352 ---------- ---------- ---------- ---------- Loss from operations (38,318) (28,682) (103,325) (79,352) Other income, net 3,752 3,204 11,785 6,985 Net loss $ (34,566) $ (25,478) $ (91,540) $ (72,367) ========== ========== ========== ========== Other comprehensive income: Unrealized gain on investments 978 198 464 922 ---------- ---------- ---------- ---------- Comprehensive loss $ (33,588) $ (25,280) $ (91,076) $ (71,445) ========== ========== ========== ========== Net loss per share, basic and diluted $ (0.49) $ (0.44) $ (1.32) $ (1.46) ========== ========== ========== ========== Weighted-average shares outstanding, basic and diluted 70,542,684 57,402,226 69,417,672 49,424,418 ========== ========== ========== ==========

ORIC(R) Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November: